BNA Books publishes the 2009 Cumulative Supplement to Pharmaceutical Patent Law

BNA BooksOct 15 2009

The 2009 Cumulative Supplement to Pharmaceutical Patent Law delivers the latest legal developments in pharmaceutical patent law. Published by BNA Books, a division of BNA, Pharmaceutical Patent Law is supplemented annually and provides complete coverage of intricate topics, including the antitrust implications of patent settlements; the experimental use privilege; and international aspects of the field, including comparative data protection laws, the benefits and limitations of the Paris Convention, the Patent Cooperation Treaty, Foreign Filing Licenses, regional agreements, and the TRIPS agreement.

The 2009 Cumulative Supplement includes the following new information:

• Legislative developments in the 111th Congress concerning patents, follow-on biologics, and Hatch-Waxman reform
• The continuing impact of Supreme Court precedent upon pharmaceutical patent law, including the law of obviousness and declaratory judgment jurisdiction
• The new rules concerning the extension of the Hatch-Waxman Act's 30-month stay of marketing approval
• Coverage of judicial reaction to concerns over baseless Paragraph IV ANDA filings
• Updated information on the construction of pharmaceutical patent claims

Pharmaceutical Patent Law not only reviews current issues of importance, but identifies topics such as parallel importation and authorized generics that are likely to be of growing significance. The treatise is invaluable to the busy practitioner who must keep on track in this evolving area of the law. The author, Professor John R. Thomas, is a member of the faculty of Georgetown University Law Center, Washington, DC, where he teaches courses in both patent and food and drug law. A widely published author in the field of pharmaceutical patent law, he frequently serves as a Special Master in patent litigation before the federal courts.